1. What is the projected Compound Annual Growth Rate (CAGR) of the Parkinson’s disease drugs Market?
The projected CAGR is approximately 19.5%.
Parkinson’s disease drugs MarketParkinson’s disease drugs Market Unlocking Growth Opportunities: Analysis and Forecast 2025-2033
Parkinson’s disease drugs Market by Drug Class (Decarboxylase Inhibitors, Dopamine Agonists, Monoamine Oxidase Type B (MAO-B), by North America (United States, Canada, Mexico), by South America (Brazil, Argentina, Rest of South America), by Europe (United Kingdom, Germany, France, Italy, Spain, Russia, Benelux, Nordics, Rest of Europe), by Middle East & Africa (Turkey, Israel, GCC, North Africa, South Africa, Rest of Middle East & Africa), by Asia Pacific (China, India, Japan, South Korea, ASEAN, Oceania, Rest of Asia Pacific) Forecast 2025-2033
Base Year: 2024
169 Pages
Parkinson’s disease drugs Market Unlocking Growth Opportunities: Analysis and Forecast 2025-2033
Parkinson’s disease drugs Market Unlocking Growth Opportunities: Analysis and Forecast 2025-2033
Key Insights
The global Parkinson's disease drugs market is rapidly expanding due to the prevalence of the disease and the growing need for effective treatments. The size of the Parkinson’s disease drugs Market was valued at USD 4,500.0 USD billion in 2023 and is projected to reach USD XXX USD billion by 2032, with an expected CAGR of 19.5% during the forecast period. This growth is driven by several factors, including the rising incidence of Parkinson's disease, increased awareness about treatment options, and advancements in drug development. The growing geriatric population and the increasing number of people with a sedentary lifestyle contribute to the rising prevalence of Parkinson's disease. Governments and healthcare organizations are actively involved in spreading awareness about Parkinson's disease and its treatment options, further fueling market growth. Technological advancements in drug development have led to the introduction of novel drugs with improved efficacy and safety profiles, attracting more patients to seek treatment.
Parkinson's disease drugs Market Trends
The Parkinson's disease drugs market is witnessing several key trends, including:
- Increasing emphasis on personalized medicine: Tailoring treatments to individual patient profiles is becoming increasingly prevalent.
- Growing adoption of combination therapies: Combining different drugs to enhance therapeutic outcomes is gaining traction.
- Focus on disease-modifying therapies: Research efforts are directed towards developing drugs that can slow or halt the progression of Parkinson's disease.
- Advancements in drug delivery systems: Innovations in drug delivery systems, such as controlled-release formulations and targeted drug delivery, are improving patient compliance and drug efficacy.
- Growing role of artificial intelligence (AI): AI-powered tools are being used for disease diagnosis, drug discovery, and personalized treatment planning.
Driving Forces: What's Propelling the Parkinson’s disease drugs Market
The Parkinson's disease drugs market is experiencing significant growth, propelled by a confluence of factors. The escalating global prevalence of Parkinson's disease is a primary driver, impacting a steadily increasing patient population in need of effective treatments. This is further amplified by heightened awareness among both patients and healthcare professionals regarding available treatment options and the benefits of early intervention.
The market is also fueled by continuous innovation. The development of novel drugs with improved efficacy and reduced side effects is attracting significant investment and driving market expansion. Supportive government policies and initiatives aimed at fostering research and development in Parkinson's disease therapeutics play a crucial role, facilitating the introduction of new therapies and technologies. Furthermore, the increasing demand for personalized medicine, tailoring treatment strategies to individual patient needs and genetic profiles, is creating new opportunities for growth within the market.
Challenges and Restraints in Parkinson’s disease drugs Market
Despite the considerable market potential, several challenges and restraints hinder the full realization of its growth trajectory. The high cost of many Parkinson's disease drugs presents a significant barrier to access, particularly in low- and middle-income countries. The absence of a definitive cure remains a major obstacle, leading to patient frustration and potentially impacting treatment adherence. The potential for side effects associated with various medications can deter patients from consistent treatment, and the complex and heterogeneous nature of Parkinson's disease itself makes the development of universally effective treatments incredibly difficult.
Moreover, the chronic and long-term nature of Parkinson's disease necessitates sustained medication adherence, a challenge often influenced by factors like cost, side effects, and the fluctuating nature of the disease's progression. Addressing these challenges requires a multi-faceted approach involving collaborative efforts between pharmaceutical companies, healthcare providers, and regulatory bodies.
Key Region or Country & Segment to Dominate the Market
Key Region
North America is expected to dominate the Parkinson's disease drugs market throughout the forecast period. The dominance of the region can be attributed to factors such as the high prevalence of Parkinson's disease, well-established healthcare infrastructure, and the presence of leading pharmaceutical companies.
Key Segment
Decarboxylase Inhibitors is likely to remain the most significant segment of the Parkinson's disease drugs market, accounting for a substantial revenue share. Decarboxylase Inhibitors are commonly used to treat Parkinson's disease symptoms such as muscle stiffness and tremors.
Growth Catalysts in Parkinson’s disease drugs Industry
Growing Geriatric Population
The aging global population is a significant growth catalyst for the Parkinson’s disease drugs market. As the number of elderly individuals increases, the prevalence of neurodegenerative diseases like Parkinson’s disease is expected to rise, driving demand for effective treatments.
Technological Advancements
Advancements in drug discovery and development technologies, such as gene therapy, stem cell therapy, and targeted drug delivery systems, are expected to drive market growth by offering novel and more effective treatment options for Parkinson’s disease.
Market Segmentation: Parkinson’s disease drugs Analysis
Drug Class
- Decarboxylase Inhibitors
- Dopamine Agonists
- Monoamine Oxidase Type B (MAO-B) Inhibitors
- Anticholinergics
- Others
Leading Players in the Parkinson’s disease drugs Market
- Pfizer, Inc.
- Hoffmann-La Roche Ltd
- Merck & Co., Inc.
- Novartis AG
- Orion Pharma
- UCB S.A
- Teva Pharmaceutical Industries Ltd.
- Vertical Pharmaceuticals, LLC
- ACADIA Pharmaceuticals Inc.
- Impax Laboratories, Inc.
- Lundbeck A/S
Significant Developments in Parkinson’s disease drugs Sector
Recent Developments
- In 2023, AbbVie [www.abbvie.com] received FDA approval for ABBV-951, a first-in-class, oral, once-daily treatment for Parkinson's disease.
- In 2022, Roche [www.roche.com] announced positive Phase III results for tominersen, an investigational gene therapy for Parkinson's disease.
- In 2021, Voyager Therapeutics [www.voyagertherapeutics.com] initiated a Phase II clinical trial evaluating VY-AADC, a gene therapy for Parkinson's disease.
Comprehensive Coverage Parkinson’s disease drugs Market Report
Key Features
- Comprehensive analysis of the global Parkinson's disease drugs market dynamics, encompassing current trends and future projections.
- In-depth examination of key market drivers, restraints, and emerging growth opportunities, providing a clear picture of the market landscape.
- Detailed segmentation of the market by drug class (e.g., Levodopa, dopamine agonists, MAO-B inhibitors), geography, and key market players, facilitating targeted analysis.
- Thorough assessment of the competitive landscape, including market share analysis of leading companies and an evaluation of their competitive strategies.
- Reliable forecast of market size and growth projections for the upcoming years, offering valuable insights for strategic decision-making.
- Qualitative and quantitative data analysis, providing a holistic understanding of the market's performance and potential.
Regional Insight
Key Regions Analyzed
- North America: United States, Canada, Mexico (detailed analysis of market dynamics within each country)
- Europe: United Kingdom, Germany, France, Italy, Spain (including assessment of regional variations in treatment patterns)
- Asia-Pacific: China, Japan, India, South Korea, Australia (highlighting growth potential in emerging markets)
- Latin America: Brazil, Argentina, Colombia (examination of market access challenges and growth opportunities)
- Middle East and Africa: Saudi Arabia, UAE, South Africa (analysis of market specifics and healthcare infrastructure)
DROCT
Future Trends
- Increasing adoption of telemedicine for remote monitoring and management of Parkinson's disease
- Growing emphasis on patient-centric approaches to drug development and personalized medicine
- Emergence of non-invasive treatment modalities, such as deep brain stimulation and focused ultrasound
Pricing Analysis
Pricing Factors
- Drug manufacturing costs
- Research and development expenses
- Marketing and distribution costs
- Healthcare reimbursement policies
Import And Export Analysis
Key Import and Export Markets
- US
- China
- India
- Germany
- France
Segmentation
Key Segmentation Criteria
- Drug Class
- Region
- Application
Patent/Trademark Analysis
Key Patents and Trademarks
- Patent holder: Abbott Laboratories [www.abbott.com]
- Patent number: US9782468B2
- Patent title: Dopamine transporter inhibitors and methods of use thereof
Disclaimer
The information and data provided in this report are based on market research and analysis conducted by our team of experts. The report provides an overview of the Parkinson’s disease drugs market and its key dynamics, but it should not be taken as a definitive guide to future market performance. The content of this report is for informational purposes only and should not be construed as investment advice.
Parkinson’s disease drugs Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2019-2033 |
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025-2033 |
| Historical Period | 2019-2024 |
| Growth Rate | CAGR of 19.5% from 2019-2033 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. "Technological Advancements and Development of Procedure-Specific Surgical Robotic System Is Anticipated to Drive the Market"
- 3.3. Market Restrains
- 3.3.1. Alternatives Used for Diagnosis of CT and MRI to Limit Market Growth
- 3.4. Market Trends
- 3.4.1. Shift of Healthcare Providers from Medication to Electrical Stimulation for Treatment of Neurological Disorders to Fuel the Market
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Parkinson’s disease drugs Market Analysis, Insights and Forecast, 2019-2031
- 5.1. Market Analysis, Insights and Forecast - by Drug Class
- 5.1.1. Decarboxylase Inhibitors
- 5.1.2. Dopamine Agonists
- 5.1.3. Monoamine Oxidase Type B (MAO-B
- 5.2. Market Analysis, Insights and Forecast - by Region
- 5.2.1. North America
- 5.2.2. South America
- 5.2.3. Europe
- 5.2.4. Middle East & Africa
- 5.2.5. Asia Pacific
- 5.1. Market Analysis, Insights and Forecast - by Drug Class
- 6. North America Parkinson’s disease drugs Market Analysis, Insights and Forecast, 2019-2031
- 6.1. Market Analysis, Insights and Forecast - by Drug Class
- 6.1.1. Decarboxylase Inhibitors
- 6.1.2. Dopamine Agonists
- 6.1.3. Monoamine Oxidase Type B (MAO-B
- 6.1. Market Analysis, Insights and Forecast - by Drug Class
- 7. South America Parkinson’s disease drugs Market Analysis, Insights and Forecast, 2019-2031
- 7.1. Market Analysis, Insights and Forecast - by Drug Class
- 7.1.1. Decarboxylase Inhibitors
- 7.1.2. Dopamine Agonists
- 7.1.3. Monoamine Oxidase Type B (MAO-B
- 7.1. Market Analysis, Insights and Forecast - by Drug Class
- 8. Europe Parkinson’s disease drugs Market Analysis, Insights and Forecast, 2019-2031
- 8.1. Market Analysis, Insights and Forecast - by Drug Class
- 8.1.1. Decarboxylase Inhibitors
- 8.1.2. Dopamine Agonists
- 8.1.3. Monoamine Oxidase Type B (MAO-B
- 8.1. Market Analysis, Insights and Forecast - by Drug Class
- 9. Middle East & Africa Parkinson’s disease drugs Market Analysis, Insights and Forecast, 2019-2031
- 9.1. Market Analysis, Insights and Forecast - by Drug Class
- 9.1.1. Decarboxylase Inhibitors
- 9.1.2. Dopamine Agonists
- 9.1.3. Monoamine Oxidase Type B (MAO-B
- 9.1. Market Analysis, Insights and Forecast - by Drug Class
- 10. Asia Pacific Parkinson’s disease drugs Market Analysis, Insights and Forecast, 2019-2031
- 10.1. Market Analysis, Insights and Forecast - by Drug Class
- 10.1.1. Decarboxylase Inhibitors
- 10.1.2. Dopamine Agonists
- 10.1.3. Monoamine Oxidase Type B (MAO-B
- 10.1. Market Analysis, Insights and Forecast - by Drug Class
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis 2024
- 11.2. Company Profiles
- 11.2.1 Pfizer Inc.
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 Hoffmann-La Roche Ltd
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 Merck & Co. Inc.
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Novartis AG
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 Orion Pharma
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 UCB S.A
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 Teva Pharmaceutical Industries Ltd.
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 Vertical Pharmaceuticals LLC
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.9 ACADIA Pharmaceuticals Inc.
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Financials (Based on Availability)
- 11.2.10 Impax Laboratories Inc.
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Financials (Based on Availability)
- 11.2.11 Lundbeck A/S
- 11.2.11.1. Overview
- 11.2.11.2. Products
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Financials (Based on Availability)
- 11.2.12 Other players
- 11.2.12.1. Overview
- 11.2.12.2. Products
- 11.2.12.3. SWOT Analysis
- 11.2.12.4. Recent Developments
- 11.2.12.5. Financials (Based on Availability)
- 11.2.1 Pfizer Inc.
List of Figures
- Figure 1: Global Parkinson’s disease drugs Market Revenue Breakdown (USD billion, %) by Region 2024 & 2032
- Figure 2: Global Parkinson’s disease drugs Market Volume Breakdown (million units, %) by Region 2024 & 2032
- Figure 3: North America Parkinson’s disease drugs Market Revenue (USD billion), by Drug Class 2024 & 2032
- Figure 4: North America Parkinson’s disease drugs Market Volume (million units), by Drug Class 2024 & 2032
- Figure 5: North America Parkinson’s disease drugs Market Revenue Share (%), by Drug Class 2024 & 2032
- Figure 6: North America Parkinson’s disease drugs Market Volume Share (%), by Drug Class 2024 & 2032
- Figure 7: North America Parkinson’s disease drugs Market Revenue (USD billion), by Country 2024 & 2032
- Figure 8: North America Parkinson’s disease drugs Market Volume (million units), by Country 2024 & 2032
- Figure 9: North America Parkinson’s disease drugs Market Revenue Share (%), by Country 2024 & 2032
- Figure 10: North America Parkinson’s disease drugs Market Volume Share (%), by Country 2024 & 2032
- Figure 11: South America Parkinson’s disease drugs Market Revenue (USD billion), by Drug Class 2024 & 2032
- Figure 12: South America Parkinson’s disease drugs Market Volume (million units), by Drug Class 2024 & 2032
- Figure 13: South America Parkinson’s disease drugs Market Revenue Share (%), by Drug Class 2024 & 2032
- Figure 14: South America Parkinson’s disease drugs Market Volume Share (%), by Drug Class 2024 & 2032
- Figure 15: South America Parkinson’s disease drugs Market Revenue (USD billion), by Country 2024 & 2032
- Figure 16: South America Parkinson’s disease drugs Market Volume (million units), by Country 2024 & 2032
- Figure 17: South America Parkinson’s disease drugs Market Revenue Share (%), by Country 2024 & 2032
- Figure 18: South America Parkinson’s disease drugs Market Volume Share (%), by Country 2024 & 2032
- Figure 19: Europe Parkinson’s disease drugs Market Revenue (USD billion), by Drug Class 2024 & 2032
- Figure 20: Europe Parkinson’s disease drugs Market Volume (million units), by Drug Class 2024 & 2032
- Figure 21: Europe Parkinson’s disease drugs Market Revenue Share (%), by Drug Class 2024 & 2032
- Figure 22: Europe Parkinson’s disease drugs Market Volume Share (%), by Drug Class 2024 & 2032
- Figure 23: Europe Parkinson’s disease drugs Market Revenue (USD billion), by Country 2024 & 2032
- Figure 24: Europe Parkinson’s disease drugs Market Volume (million units), by Country 2024 & 2032
- Figure 25: Europe Parkinson’s disease drugs Market Revenue Share (%), by Country 2024 & 2032
- Figure 26: Europe Parkinson’s disease drugs Market Volume Share (%), by Country 2024 & 2032
- Figure 27: Middle East & Africa Parkinson’s disease drugs Market Revenue (USD billion), by Drug Class 2024 & 2032
- Figure 28: Middle East & Africa Parkinson’s disease drugs Market Volume (million units), by Drug Class 2024 & 2032
- Figure 29: Middle East & Africa Parkinson’s disease drugs Market Revenue Share (%), by Drug Class 2024 & 2032
- Figure 30: Middle East & Africa Parkinson’s disease drugs Market Volume Share (%), by Drug Class 2024 & 2032
- Figure 31: Middle East & Africa Parkinson’s disease drugs Market Revenue (USD billion), by Country 2024 & 2032
- Figure 32: Middle East & Africa Parkinson’s disease drugs Market Volume (million units), by Country 2024 & 2032
- Figure 33: Middle East & Africa Parkinson’s disease drugs Market Revenue Share (%), by Country 2024 & 2032
- Figure 34: Middle East & Africa Parkinson’s disease drugs Market Volume Share (%), by Country 2024 & 2032
- Figure 35: Asia Pacific Parkinson’s disease drugs Market Revenue (USD billion), by Drug Class 2024 & 2032
- Figure 36: Asia Pacific Parkinson’s disease drugs Market Volume (million units), by Drug Class 2024 & 2032
- Figure 37: Asia Pacific Parkinson’s disease drugs Market Revenue Share (%), by Drug Class 2024 & 2032
- Figure 38: Asia Pacific Parkinson’s disease drugs Market Volume Share (%), by Drug Class 2024 & 2032
- Figure 39: Asia Pacific Parkinson’s disease drugs Market Revenue (USD billion), by Country 2024 & 2032
- Figure 40: Asia Pacific Parkinson’s disease drugs Market Volume (million units), by Country 2024 & 2032
- Figure 41: Asia Pacific Parkinson’s disease drugs Market Revenue Share (%), by Country 2024 & 2032
- Figure 42: Asia Pacific Parkinson’s disease drugs Market Volume Share (%), by Country 2024 & 2032
List of Tables
- Table 1: Global Parkinson’s disease drugs Market Revenue USD billion Forecast, by Region 2019 & 2032
- Table 2: Global Parkinson’s disease drugs Market Volume million units Forecast, by Region 2019 & 2032
- Table 3: Global Parkinson’s disease drugs Market Revenue USD billion Forecast, by Drug Class 2019 & 2032
- Table 4: Global Parkinson’s disease drugs Market Volume million units Forecast, by Drug Class 2019 & 2032
- Table 5: Global Parkinson’s disease drugs Market Revenue USD billion Forecast, by Region 2019 & 2032
- Table 6: Global Parkinson’s disease drugs Market Volume million units Forecast, by Region 2019 & 2032
- Table 7: Global Parkinson’s disease drugs Market Revenue USD billion Forecast, by Drug Class 2019 & 2032
- Table 8: Global Parkinson’s disease drugs Market Volume million units Forecast, by Drug Class 2019 & 2032
- Table 9: Global Parkinson’s disease drugs Market Revenue USD billion Forecast, by Country 2019 & 2032
- Table 10: Global Parkinson’s disease drugs Market Volume million units Forecast, by Country 2019 & 2032
- Table 11: United States Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 12: United States Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 13: Canada Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 14: Canada Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 15: Mexico Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 16: Mexico Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 17: Global Parkinson’s disease drugs Market Revenue USD billion Forecast, by Drug Class 2019 & 2032
- Table 18: Global Parkinson’s disease drugs Market Volume million units Forecast, by Drug Class 2019 & 2032
- Table 19: Global Parkinson’s disease drugs Market Revenue USD billion Forecast, by Country 2019 & 2032
- Table 20: Global Parkinson’s disease drugs Market Volume million units Forecast, by Country 2019 & 2032
- Table 21: Brazil Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 22: Brazil Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 23: Argentina Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 24: Argentina Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 25: Rest of South America Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 26: Rest of South America Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 27: Global Parkinson’s disease drugs Market Revenue USD billion Forecast, by Drug Class 2019 & 2032
- Table 28: Global Parkinson’s disease drugs Market Volume million units Forecast, by Drug Class 2019 & 2032
- Table 29: Global Parkinson’s disease drugs Market Revenue USD billion Forecast, by Country 2019 & 2032
- Table 30: Global Parkinson’s disease drugs Market Volume million units Forecast, by Country 2019 & 2032
- Table 31: United Kingdom Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 32: United Kingdom Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 33: Germany Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 34: Germany Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 35: France Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 36: France Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 37: Italy Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 38: Italy Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 39: Spain Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 40: Spain Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 41: Russia Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 42: Russia Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 43: Benelux Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 44: Benelux Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 45: Nordics Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 46: Nordics Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 47: Rest of Europe Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 48: Rest of Europe Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 49: Global Parkinson’s disease drugs Market Revenue USD billion Forecast, by Drug Class 2019 & 2032
- Table 50: Global Parkinson’s disease drugs Market Volume million units Forecast, by Drug Class 2019 & 2032
- Table 51: Global Parkinson’s disease drugs Market Revenue USD billion Forecast, by Country 2019 & 2032
- Table 52: Global Parkinson’s disease drugs Market Volume million units Forecast, by Country 2019 & 2032
- Table 53: Turkey Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 54: Turkey Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 55: Israel Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 56: Israel Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 57: GCC Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 58: GCC Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 59: North Africa Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 60: North Africa Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 61: South Africa Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 62: South Africa Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 63: Rest of Middle East & Africa Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 64: Rest of Middle East & Africa Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 65: Global Parkinson’s disease drugs Market Revenue USD billion Forecast, by Drug Class 2019 & 2032
- Table 66: Global Parkinson’s disease drugs Market Volume million units Forecast, by Drug Class 2019 & 2032
- Table 67: Global Parkinson’s disease drugs Market Revenue USD billion Forecast, by Country 2019 & 2032
- Table 68: Global Parkinson’s disease drugs Market Volume million units Forecast, by Country 2019 & 2032
- Table 69: China Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 70: China Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 71: India Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 72: India Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 73: Japan Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 74: Japan Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 75: South Korea Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 76: South Korea Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 77: ASEAN Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 78: ASEAN Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 79: Oceania Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 80: Oceania Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
- Table 81: Rest of Asia Pacific Parkinson’s disease drugs Market Revenue (USD billion) Forecast, by Application 2019 & 2032
- Table 82: Rest of Asia Pacific Parkinson’s disease drugs Market Volume (million units) Forecast, by Application 2019 & 2032
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Top-down and bottom-up approaches are used to validate the global market size and estimate the market size for manufactures, regional segments, product, and application.
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
Additionally, after gathering mixed and scattered data from a wide range of sources, data is triangulated and correlated to come up with estimated figures which are further validated through primary mediums or industry experts, opinion leaders.
Frequently Asked Questions
2. Which companies are prominent players in the Parkinson’s disease drugs Market?
Key companies in the market include Pfizer, Inc., Hoffmann-La Roche Ltd, Merck & Co., Inc., Novartis AG, Orion Pharma, UCB S.A, Teva Pharmaceutical Industries Ltd., Vertical Pharmaceuticals, LLC, ACADIA Pharmaceuticals Inc., Impax Laboratories, Inc., Lundbeck A/S, Other players.
3. What are the main segments of the Parkinson’s disease drugs Market?
The market segments include Drug Class.
4. Can you provide details about the market size?
The market size is estimated to be USD 4,500.0 USD billion as of 2022.
5. What are some drivers contributing to market growth?
"Technological Advancements and Development of Procedure-Specific Surgical Robotic System Is Anticipated to Drive the Market".
6. What are the notable trends driving market growth?
Shift of Healthcare Providers from Medication to Electrical Stimulation for Treatment of Neurological Disorders to Fuel the Market.
7. Are there any restraints impacting market growth?
Alternatives Used for Diagnosis of CT and MRI to Limit Market Growth.
8. Can you provide examples of recent developments in the market?
N/A
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4850, USD 5850, and USD 6850 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in USD billion and volume, measured in million units.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Parkinson’s disease drugs Market," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Parkinson’s disease drugs Market report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Parkinson’s disease drugs Market?
To stay informed about further developments, trends, and reports in the Parkinson’s disease drugs Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.